Page last updated: 2024-11-03

riluzole and TDP-43 Proteinopathies

riluzole has been researched along with TDP-43 Proteinopathies in 1 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

TDP-43 Proteinopathies: Diseases characterized by the presence of abnormally phosphorylated, ubiquitinated, and cleaved DNA-binding protein TDP-43 in affected brain and spinal cord. Inclusions of the pathologic protein in neurons and glia, without the presence of AMYLOID, is the major feature of these conditions, thus making these proteinopathies distinct from most other neurogenerative disorders in which protein misfolding leads to brain amyloidosis. Both frontotemporal lobar degeneration and AMYOTROPHIC LATERAL SCLEROSIS exhibit this common method of pathogenesis and thus they may represent two extremes of a continuous clinicopathological spectrum of one disease.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jung, HH1
Neumann, M1
Bloch, KE1

Reviews

1 review available for riluzole and TDP-43 Proteinopathies

ArticleYear
[Amyotrophic lateral sclerosis--diagnosis and treatment].
    Praxis, 2012, Jul-04, Volume: 101, Issue:14

    Topics: Activities of Daily Living; Aged; Amyotrophic Lateral Sclerosis; Animals; Cause of Death; Cross-Sect

2012